Generation Lab
-72%
est. 2Y upside i
Generation Lab aims to extend the human healthspan with the first test based on clinically relevant biological evidence that measures individuals’ biological age progression and risk of disease so everyone can live longer, healthier lives.
Rank
#278
Sector
HealthTech
Est. Liquidity
~6Y
Data Quality
Data: MediumGeneration Lab presents a strong upside opportunity driven by its highly differentiated, patented SystemAge™ platform in the rapidly expanding longevity market, backed by a strong investor syndicate.
Last updated: March 10, 2026
Generation Lab's SystemAge™ platform achieves widespread adoption, expanding beyond clinic partnerships into direct-to-consumer channels and securing major insurance coverage. This drives revenue to over $100M by 2028, justifying a $270M+ valuation at a premium multiple due to its strong moat and market leadership in a rapidly growing longevity sector.
The company maintains its strong position within the specialized longevity diagnostic market, continuing to grow clinic partnerships and subscriber base. Revenue reaches approximately $40M-$50M by 2028, leading to an acquisition or next funding round at a $120M valuation, reflecting solid execution but facing some competitive and regulatory headwinds.
Regulatory challenges intensify, or a dominant incumbent like Labcorp or Quest Diagnostics launches a directly competing, lower-cost epigenetic biological age test. This significantly curtails Generation Lab's growth, leading to a down round where the company struggles to exceed $10M in revenue, resulting in a valuation of $12M or less, severely impairing common stock value given the $15M liquidation preference.
Preference Stack Risk
highWith $15M in total funding on an assumed $60M post-money valuation, investors hold a 25% liquidation preference, meaning they get $15M before common shareholders receive any proceeds in an exit scenario at or above current valuation.
Dilution Risk
moderateAs a Seed stage company, Generation Lab will require multiple future funding rounds (Series A, B, etc.) before a potential liquidity event, which will lead to further dilution for existing equity holders.
Secondary Liquidity
noneThere is currently no active secondary market for Generation Lab stock, and the company's transfer rules are unknown, limiting early liquidity options for employees.
Questions to Ask at the Interview
Strategic questions based on Generation Lab's data — designed to show you've done your homework.
- 1
“How is Generation Lab planning to navigate the complex and varying regulatory landscape for genetic and biological age testing across different states and internationally, especially as you scale?”
- 2
“With a strong competitive moat based on your patented SystemAge™ platform, what are the key strategies for expanding market penetration beyond the current 275+ clinic partners and into broader consumer markets?”
- 3
“Given the Seed funding round in late 2025, what is the anticipated timeline for the next funding round (Series A) and how is the company thinking about the long-term path to a liquidity event for employees?”
Community
Valuation Sentiment
Our model estimates -72% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.